New medication that can cut body weight by 23% could radically reduce the number of people who are obese. Tirzepatide is ...
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...
CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...
SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...
Payers and employers have tightened access to the glucagon-like peptide-1 receptor agonist class once these therapies became ...
The best online providers offer strong support services to help you succeed in your GLP-1 weight loss journey.
Good afternoon, and welcome to Fractyl Health's Third Quarter Financial Results and Business Updates Call. As a reminder, this conference call is being recorded. [Operator Instructions]. I will now ...
With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...
Eli Lilly ( LLY -1.63%) and Microsoft ( MSFT 1.20%) are two high-flying dividend stocks in the S&P 500 index. Here's why the ...
and tirzepatide (Mounjaro and Zepbound; Eli Lilly), a dual GLP-1/glucose-dependent insulinotropic peptide (GIP) agonist. That ...
Diabetes and weight-loss drug tirzepatide (Mounjaro, Zepbound) was listed as a contributing factor in the death of a 58-year-old nurse from Scotland who died of multiple organ failure, septic shock, ...